GSK2795039

Research use only, not for human use.

GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption. GSK2795039 decreases apoptosis. GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) (pIC50: 6 in different cell-free assays). GSK2795039 (25 μM; 24 hours) decreases the combinatory effect of FeSO4 and LPS-increased levels of apoptosis.

GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption. GSK2795039 decreases apoptosis. GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) (pIC50: 6 in different cell-free assays). GSK2795039 (25 μM; 24 hours) decreases the combinatory effect of FeSO4 and LPS-increased levels of apoptosis. It also reduced the presence of caspase-3-positive PC12 cells.GSK2795039 (i.p.; 100 mg/kg; 1 hour before) reduces activity in a murine model of acute pancreatitis. It also decreases the levels of serum amylase triggered by systemic injection of cerulein.

GSK2795039 (25 μM; 24 hours) reduces the combinatory effect of FeSO4 and LPS-increased levels of apoptosis and reduced the presence of caspase-3-positive PC12 cells. Apoptosis Analysis Cell Line:PC12 cells Concentration:25 μM Incubation Time:24 hours Result:Reduced apoptosis among PC12 cells.

GSK2795039 (intraperitoneal injection; 100 mg/kg; 1 hour before) decreases activity in a murine model of acute pancreatitis, reducing the levels of serum amylase triggered by systemic injection of cerulein. Animal Model:C57BL6 mice Dosage:100 mg/kg Administration:Intraperitoneal injection; 100 mg/kg; 1 hour before Result:Caused 50% reduction in the level of serum amylase activity.

——

Membrane Transporter/Ion Channel

NADPH

NADPH| apoptosis| ROS

——

——

1415925-18-6

450.56

C23H26N6O2S

>98% (HPLC)

DMSO:31 mg/mL(68.8 mM)

CC(C)n1cc(-c2ccc3CCN(C)c3c2)c2c(NS(=O)(=O)c3ccn(C)n3)ccnc12

——

(-20℃)

With Ice Pack

≥ 2 years